Initiating Empagliflozin and Sacubitril/Valsartan Early After Acute Myocardial Infarction: Mechanistic Study
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.124.040214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Daina Martínez-Falguera und 23 weiteren Autor:innen. Beteiligte Einrichtung: ICREC Research Program Germans Trias i Pujol Research Institute (IGTP) Barcelona Spain. Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, Biphenyl Compounds, Aminobutyrates. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Empagliflozin and sacubitril/valsartan are established in heart failure treatment, but their effects after myocardial infarction (MI) are less clear. This study evaluated early empagliflozin initiation, with or without sacubitril/valsartan, on post‐MI inflammation, oxidative stress, metabolism, fibrosis, cardiac function, and ventricular tachycardia (VT) risk in a pig model.
Methods
A total of 24 of 30 pigs survived the MI procedure and were subsequently randomized to receive beta‐blocker treatment alone (control‐MI), beta‐blocker+empagliflozin, or beta‐blocker+empagliflozin+sacubitril/valsartan. Immune response, metabolic profile, and cardiac function were monitored. At 30 days after MI, programmed electrical stimulation and high‐density mapping were performed and VT inducibility was assessed. Tissue samples were collected for cardiac inflammation, oxidative stress, and metabolic analyses.
Results
Empagliflozin reduced circulating leukocytes at 2 and 15 days after MI ( P =0.010 and P =0.050, respectively) and decreased C‐C chemokine receptor 2+ monocytes at 15 days ( P =0.049). Nitric oxide bioavailability increased in remote myocardium ( P =0.059), along with cardioprotective liver lipids and collagen III in the myocardial scar ( P =0.023). No effect on cardiac function or VT inducibility was observed at 30 days. With empagliflozin+sacubitril/valsartan, scar collagen I decreased ( P =0.082), left ventricular compliance improved ( P =0.029), electrophysiological remodeling improved (reduced border‐zone corridors [ P =0.006] and deceleration zones [ P =0.008]), and VT inducibility decreased ( P =0.025).
Conclusions
In this pig model of nonreperfused MI treated with beta‐blocker, early initiation of empagliflozin reduced inflammation, improved nitric oxide bioavailability, increased protective liver lipids, and modified scar composition without affecting cardiac function or VT risk. With empagliflozin+sacubitril/valsartan treatment, scar collagen I and VT inducibility declined and left ventricular remodeling was enhanced.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ICREC Research Program Germans Trias i Pujol Research Institute (IGTP) Barcelona Spain.
- Faculty of Medicine University of Barcelona (UB) Spain.
- Heart Institute (iCOR), Germans Trias i Pujol University Hospital Barcelona Spain.
- CIBER Cardiovascular, Instituto de Salud Carlos III Madrid Spain.
- Department of Immunobiology University of Lausanne Epalinges Vaud Switzerland.
- Faculty of Medicine University of Vic-Central University of Catalonia (UVic-UCC), Vic Barcelona Spain.
ORCID-Profile: Daina Martínez-Falguera, Júlia Aranyó, Albert Teis, Elena Revuelta-Lopez, Marta Monguió-Tortajada, Edgar Fadeuilhe, Oriol Rodríguez-Leor, Francesc Poblador, Borja Montejo, Santiago Roura, Roger Villuendas, Axel Sarrias, Victor Bazan, Victoria Delgado, Montserrat Rigol, Neus Martinez-Micaelo, Núria Amigó, Antoni Bayes-Genis, Felipe Bisbal, Carolina Gálvez-Montón
Zitieren
APA
Martínez-Falguera, D., Aranyó, J., Ferrer-Curriu, G., Teis, A., Revuelta-Lopez, E., Diaz-Güemes, I., Monguió-Tortajada, M., Fadeuilhe, E., Rodríguez-Leor, O., Poblador, F., Montejo, B., Roura, S., Villuendas, R., Sarrias, A., Bazan, V., Jorge, E., Delgado, V., Jimenez-Trinidad, F. R., Rigol, M., …, & Gálvez-Montón, C. (2025). Initiating Empagliflozin and Sacubitril/Valsartan Early After Acute Myocardial Infarction: Mechanistic Study. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.040214
Vancouver
Martínez-Falguera D, Aranyó J, Ferrer-Curriu G, Teis A, Revuelta-Lopez E, Diaz-Güemes I, et al. Initiating Empagliflozin and Sacubitril/Valsartan Early After Acute Myocardial Infarction: Mechanistic Study. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.040214
BibTeX
@article{MartnezFalguera2025,
author = {Martínez-Falguera, Daina and Aranyó, Júlia and Ferrer-Curriu, Gemma and Teis, Albert and Revuelta-Lopez, Elena and Diaz-Güemes, Idoia and Monguió-Tortajada, Marta and Fadeuilhe, Edgar and Rodríguez-Leor, Oriol and Poblador, Francesc and Montejo, Borja and Roura, Santiago and Villuendas, Roger and Sarrias, Axel and Bazan, Victor and Jorge, Esther and Delgado, Victoria and Jimenez-Trinidad, Francisco Rafael and Rigol, Montserrat and Martinez-Micaelo, Neus and Amigó, Núria and Bayes-Genis, Antoni and Bisbal, Felipe and Gálvez-Montón, Carolina},
title = {Initiating Empagliflozin and Sacubitril/Valsartan Early After Acute Myocardial Infarction: Mechanistic Study},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.040214}
}
EUVIMED